Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)Carsten Müller‐Tidow, Wolfgang E. Berdel, Christoph Röllig et al.|Blood|2014Cited by 1
DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapyPetra Tschanter, Carsten Müller‐Tidow, Utz Krug et al.|Kölner Universitäts PublikationsServer (Universität zu Köln)|2015Cited by 0